Ambrisentan for early low-risk pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a medicine called ambrisentan for people with early, low-risk pulmonary arterial hypertension. The goal is to see if starting treatment early can help manage the condition before it gets worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of pulmonary arterial hypertension (PAH) that is at low risk, meaning your symptoms are mild and your condition is fairly stable.
- You must have had a right heart catheterization (a test that measures pressure in your heart and lungs) within the last 7 days, showing specific mild elevations in pressure.
- You must not have taken any PAH-specific medications like bosentan, ambrisentan, sildenafil, tadalafil, or riociguat before joining the study.
- You cannot join if you have other types of pulmonary hypertension (like from heart or lung disease), or if you have severe anemia, kidney problems, liver problems, or very low or very high blood pressure.
- You must be willing to give written consent and follow all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This study looks at how changing from one PAH medicine (ambrisentan) to another (bosentan) affects your disease risk over time. It compares people who made the switch to those who stayed on ambrisentan.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.